基于迁移学习的MHC-I型抗原表位呈递预测

doi:10.16288/j.yczz.19-155

遗传 ›› 2019, Vol. 41 ›› Issue (11): 1041-1049.doi: 10.16288/j.yczz.19-155

基于迁移学习的MHC-I型抗原表位呈递预测

胡伟澎^1,^2,³,李佑平^2,^3,⁴,张秀清^2,^3,⁴()

^1. 华南理工大学生物科学与工程学院,广州 510006
^2. 深圳华大生命科学研究院,深圳 518083
^3. 华大吉诺因,武汉 4300794
^4. 中国科学院大学华大教育中心,深圳 518083

收稿日期:2019-06-21 修回日期:2019-09-17 出版日期:2019-11-20 发布日期:2019-10-08
通讯作者: 张秀清 E-mail:zhangxq@genomics.cn
作者简介:胡伟澎,硕士研究生,专业方向：基因组学。E-mail: huweipeng@genomics.cn|李佑平,硕士研究生,专业方向：基因组学。E-mail: liyouping@genomics.cn
胡伟澎和李佑平并列第一作者。
基金资助:
国家自然科学基金项目编号：(81702826);国家自然科学基金项目编号：(81772910);深圳市科创委项目编号：(JCYJ20170303151334808);深圳市经信委项目资助编号：(20170731162715261)

MHC-I epitope presentation prediction based on transfer learning

Weipeng Hu^1,^2,³,Youping Li^2,^3,⁴,Xiuqing Zhang^2,^3,⁴()

^1. School of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, China
^2. BGI-Shenzhen, Shenzhen 518083, China
^3. BGI-GenoImmune, Wuhan 4300794, China
^4. BGI Education Center, University of Chinese Academy of Sciences, Shenzhen 518083, China

Received:2019-06-21 Revised:2019-09-17 Online:2019-11-20 Published:2019-10-08
Contact: Zhang Xiuqing E-mail:zhangxq@genomics.cn
Supported by:
Supported by the National Natural Science Foundation of China Nos.(81702826);Supported by the National Natural Science Foundation of China Nos.(81772910);Science, Technology and Innovation Commission of Shenzhen Municipality No.(JCYJ20170303151334808);and Shenzhen Municipal Government of China No.(20170731162715261)

摘要/Abstract

摘要：

基于新抗原的肿瘤免疫治疗,抗原呈递的准确预测是筛选T细胞特异性表位的关键步骤。质谱鉴定的表位数据对建立抗原呈递预测模型具有重要价值。尽管近年来质谱数据的积累持续增加,但是大部分人类白细胞抗原(human leukocyte antigen, HLA)分型所对应的多肽数量相对较少,无法建立可靠的预测模型。为此,本研究尝试利用迁移学习的方法,先利用混合分型的表位数据建立模型以识别抗原表位的共同特征,在此预训练模型的基础上再利用分型特异性数据建立抗原呈递预测模型Pluto。在相同的验证集上,Pluto的平均0.1%阳性预测值(positive predictive value, PPV)比从头训练的模型高0.078。在外部的质谱数据独立评估上,Pluto的平均0.1% PPV为0.4255,高于从头训练模型(0.3824)和其他主流工具,包括MixMHCpred (0.3369)、NetMHCpan4.0-EL (0.4000)、NetMHCpan4.0-BA (0.3188)和MHCflurry (0.3002)。此外,在免疫原性预测评估上,Pluto相对于其他工具也能找到更多的新抗原。Pluto开源网址：https://github.com/weipenegHU/Pluto。

关键词: 免疫治疗, 新抗原, 抗原呈递, 深度学习, 迁移学习

Abstract:

Accurate epitope presentation prediction is a key procedure in tumour immunotherapies based on neoantigen for targeting T cell specific epitopes. Epitopes identified by mass spectrometry (MS) is valuable to train an epitope presentation prediction model. In spite of the accelerating accumulation of MS data, the number of epitopes that match most of human leukocyte antigens (HLAs) is relatively small, which makes it difficult to build a reliable prediction model. Therefore, this research attempted to use the transfer learning method to train a model to learn common features among the mixed allele specific epitopes. Then based on this pre-trained model, we used the allele-specific epitopes to train the final epitope presentation prediction model, termed Pluto. The average 0.1% positive predictive value (PPV) of Pluto outperformed the prediction model without pretraining with a margin of 0.078 on the same validation dataset. When evaluating Pluto on external HLA eluted ligand datasets, Pluto achieved an averaged 0.1% PPV of 0.4255, which is better than the prediction model without pretraining (0.3824) and other popular methods, including MixMHCpred (0.3369), NetMHCpan4.0-EL (0.4000), NetMHCpan4.0-BA (0.3188) and MHCflurry (0.3002). Moreover, when it comes to the evaluation of predicting immunogenicity, Pluto can identify more neoantigens than other tools. Pluto is publicly available at https://github.com/weipenegHU/Pluto.

Key words: immunotherapy, neoantigen, epitope presentation, deep learning, transfer learning

胡伟澎, 李佑平, 张秀清. 基于迁移学习的MHC-I型抗原表位呈递预测[J]. 遗传, 2019, 41(11): 1041-1049.

Weipeng Hu, Youping Li, Xiuqing Zhang. MHC-I epitope presentation prediction based on transfer learning[J]. Hereditas(Beijing), 2019, 41(11): 1041-1049.

参考文献 39

[1]	Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, Trebska-Mcgowan K, Wunderlich JR, Yang JC, Rosenberg SA . Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med, 2016,22(4):433-438.
[2]	Malekzadeh P, Pasetto A, Robbins PF, Parkhurst MR, Paria BC, Jia L, Gartner JJ, Hill V, Yu Z, Restifo NP, Sachs A, Tran E, Lo W, Somerville RPT, Rosenberg SA, Deniger DC . Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. J Clin Invest, 2019,129(3):1109-1114.
[3]	Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA . Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med, 2013,19(6):747-752.
[4]	Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, L?wer M, Bukur V, Tadmor AD, Luxemburger U, Schr?rs B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Kuhn AN, Buck J, Heesch S, Schreeb KH, Müller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Diekmann J, Ciesla J, Waksmann O, Brück A K, Witt M, Zillgen M, Rothermel A, Kasemann B, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, Gebhardt C, Grabbe S, H?ller C, Utikal J, Huber C, Loquai C, Türeci O . Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, 2017,547(7662):222-226.
[5]	Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, Wunderlich JR, Somerville RP, Rosenberg SA . Immunogenicity of somatic mutations in human gastrointestinal cancers. Science, 2015,350(6266):1387-1390.
[6]	Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, Kriley IR, Rosenberg SA . T-Cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med, 2016,375(23):2255-2262.
[7]	Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, Gartner J, Jia L, Trebska-Mcgowan K, Somerville RP, Robbins PF, Rosenberg SA, Goff SL, Feldman SA . Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med, 2018,24(6):724-730.
[8]	Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ , D'andrea AD. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/ PD-L1 in high grade serous ovarian cancer. Oncotarget, 2016,7(12):13587-13598.
[9]	Lu HZ, Wang DK, Wang Z . Correlation analysis of the prognosis of HPV positive oropharyngeal cancer patients with T cell infiltration and neoantigen load. Hereditas (Beijing), 2019,41(8):725-735.
	卢涣滋, 王迪侃, 王智 . HPV阳性口咽癌患者预后与T细胞浸润和新抗原负荷相关性分析. 遗传, 2019,41(8):725-735.
[10]	Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, Holt RA . Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res, 2014,24(5):743-750.
[11]	Shukla SA, Howitt BE, Wu CJ, Konstantinopoulos PA . Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations. Gynecol Oncol Rep, 2016,19:42-45.
[12]	Sa HL, Ma KW, Gao Y, Wang DQ . Predictive value of tumor mutation burden in immunotherapy for lung cancer. Chin J Lung Canc, 2019,22(6):380-384.
	撒焕兰, 马克威, 高勇, 王德强 . 肿瘤突变负荷对肺癌免疫治疗疗效的预测价值. 中国肺癌杂志, 2019,22(6):380-384.
[13]	Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M . NetMHCpan-4.0: Improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol, 2017,199(9):3360-3368.
[14]	Nielsen M, Andreatta M . NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med, 2016,8(1):33.
[15]	Nielsen M, Lundegaard C, Blicher T, Lamberth K, Harndahl M, Justesen S, R?der G, Peters B, Sette A, Lund O, Buus S . NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One, 2007,2(8):e796.
[16]	O'donnelL TJ, Rubinsteyn A, Bonsack M, Riemer AB, Laserson U, Hammerbacher J . MHCflurry: open-source class I MHC binding affinity prediction. Cell Syst, 2018,7(1):129-132 e4.
[17]	Bulik-Sullivan B, Busby J, Palmer CD, Davis MJ, Murphy T, Clark A, Busby M, Duke F, Yang A, Young L, Ojo NC, Caldwell K, Abhyankar J, Boucher T, Hart MG, Makarov V, Montpreville VT, Mercier O, Chan TA, Scagliotti G, Bironzo P, Novello S, Karachaliou N, Rosell R, Anderson I, Gabrail N, Hrom J, Limvarapuss C, Choquette K, Spira A, Rousseau R, Voong C, Rizvi NA, Fadel E, Frattini M, Jooss K, Skoberne M, Francis J, Yelensky R . Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. Nat Biotechnol, 2018,37(1):55-63
[18]	Gfeller D, Bassani-Sternberg M . Predicting antigen presentation—what could we learn from a million peptides? Front Immunol, 2018,9:1716.
[19]	Bassani-Sternberg M, Chong C, Guillaume P, Solleder M, Pak H, Gannon PO, Kandalaft LE, Coukos G, Gfeller D . Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity. PLoS Comput Biol, 2017,13(8):e1005725.
[20]	Gfeller D, Guillaume P, Michaux J, Pak HS, Daniel RT, Racle J, Coukos G and Bassani-Sternberg M. The length distribution and multiple specificity of naturally presented HLA-I ligands. J Immunol, 2018,201(12):3705-3716.
[21]	Pearson H, Daouda T, Granados DP, Durette C, Bonneil E, Courcelles M, Rodenbrock A, Laverdure JP, Coté C, Mader S, Lemieux S, Thibault P, Perreault C . MHC class I-associated peptides derive from selective regions of the human genome. J Clin Invest, 2016,126(12):4690-4701.
[22]	Bassani-Sternberg M, Pletscher-Frankild S, Jensen LJ, Mann M . Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteomics, 2015,14(3):658-673.
[23]	Shao W, Pedrioli PGA, Wolski W, Scurtescu C, Schmid E, Vizcaíno JA, Courcelles M, Schuster H, Kowalewski D, Marino F, Arlehamn CSL, Vaughan K, Peters B, Sette A, Ottenhoff THM, Meijgaarden KE, Nieuwenhuizen N, Kaufmann SHE, Schlapbach R, Castle JC, Nesvizhskii A I, Nielsen M, Deutsch E W, Campbell D S, Moritz R L, Zubarev R A, Ytterberg A J, Purcell A W, Marcilla M, Paradela A, Wang Q, Costello CE, Ternette N, van Veelen PA, van Els CACM, Heck AJR, de Souza GA, Sollid LM, Admon A, Stevanovic S, Rammensee HG, Thibault P, Perreault C, Bassani-Sternberg M, Aebersold R, Caron E . The SysteMHC atlas project. Nucleic Acids Res, 2018,46(D1):D1237-D1247.
[24]	Abelin JG, Keskin DB, Sarkizova S, Hartigan CR, Zhang W, Sidney J, Stevens J, Lane W, Zhang GL, Eisenhaure TM, Clauser KR, Hacohen N, Rooney MS, Carr SA, Wu CJ . Mass spectrometry profiling of HLA-Associated peptidomes in Mono-allelic cells enables more accurate epitope prediction. Immunity, 2017,46(2):315-326.
[25]	Vita R, Overton JA, Greenbaum JA, Ponomarenko J, Clark JD, Cantrell JR, Wheeler DK, Gabbard JL, Hix D, Sette A, Peters B . The immune epitope database (IEDB) 3.0. Nucleic Acids Res, 2015,43(Database issue):D405-412.
[26]	Rammensee HG, Friede T, Stevanoviíc S . MHC ligands and peptide motifs: first listing. Immunogenetics, 1995,41(4):178-228.
[27]	Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL, Appella E, Engelhard VH . Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science, 1992,255(5049):1261-1263.
[28]	Abadi M, Agarwal A, Barham P, Brevdo E, Chen Z, Citro C, Corrado GS, Davis A, Dean J, Devin M, Ghemawat S, Goodfellow I, Harp A, Irving G, Isard M, Jia YQ, Jozefowicz R, Kaiser L, Kudlur M, Levenberg J, Mane D, Monga R, Moore S, Murray D, Olah C, Schuster M, Shlens J, Steiner B, Sutskever I, Talwar K, Tucker P, Vanhoucke V, Vasudevan V, Viegas F, Vinyals O, Warden P, Wattenberg M, Wicke M, Yu Y, Zheng XQ. Tensorflow: Large-scale machine learning on heterogeneous distributed systems. arXiv preprint arXiv: 1603. 04467, 2016
[29]	Trolle T, Mcmurtrey CP, Sidney J, Bardet W, Osborn SC, Kaever T, Sette A, Hildebrand WH, Nielsen M, Peters B . The length distribution of class I-restricted T cell epitopes is determined by both peptide supply and MHC allele- specific binding preference. J Immunol, 2016,196(4):1480-1487.
[30]	Str?nen E, Toebes M, Kelderman S, van Buuren MM, Yang W, van Rooij N, Donia M, B?schen ML, Lund-Johansen F, Olweus J, Schumacher TN . Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science, 2016,352(6291):1337-1341.
[31]	Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM . Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med, 2016,22(4):433-438.
[32]	Hu WP, Qiu S, Li YP, Lin XX, Zhang L, Xiang HT, Han X, Chen L, Li S, Li WH, Ren Z, Hou GX, Lin ZL, Lu JL, Liu G, Li B, Lee LJ . EPIC: MHC-I epitope prediction integrating mass spectrometry derived motifs and tissue- specific expression profiles. bioRxiv, 2019,567081.
[33]	Nielsen M, Lundegaard C, Lund O, Kesmir C . The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics, 2005,57(1-2):33-41.
[34]	Müller M, Gfeller D, Coukos G, Bassani-Sternberg M . 'Hotspots' of antigen presentation revealed by human leukocyte antigen ligandomics for neoantigen prioritization. Front Immunol, 2017,8:1367.
[35]	Mcgranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, Mitter R, Akarca AU, Linares J, Marafioti T, Henry JY, Van Allen EM, Miao D, Schilling B, Schadendorf D, Garraway LA, Makarov V, Rizvi NA, Snyder A, Hellmann MD, Merghoub T, Wolchok JD, Shukla SA, Wu CJ, Peggs KS, Chan TA, Hadrup SR, Quezada SA, Swanton C . Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science, 2016,351(6280):1463-1469.
[36]	Calis JJ, Maybeno M, Greenbaum JA, Weiskopf D, de Silva AD, Sette A, Ke?mir C, Peters B . Properties of MHC class I presented peptides that enhance immunogenicity. PLoS ComputBiol, 2013,9(10):e1003266.
[37]	Assarsson E, Sidney J, Oseroff C, Pasquetto V, Bui HH, Frahm N, Brander C, Peters B, Grey H, Sette A . A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J Immunol, 2007,178(12):7890-7901.
[38]	Bentzen AK, Such L, Jensen KK, Marquard AM, Jessen LE, Miller NJ, Church CD, Lyngaa R, Koelle DM, Becker JC, Linnemann C, Schumacher TNM, Marcatili P, Nghiem P, Nielsen M, Hadrup SR . T cell receptor fingerprinting enables in-depth characterization of the interactions governing recognition of peptide-MHC complexes. Nat Biotechnol, 2018,36(12):1191-11996.
[39]	Bentzen AK, Marquard AM, Lyngaa R, Saini SK, Ramskov S, Donia M, Such L, Furness AJ, Mcgranahan N, Rosenthal R, Straten PT, Szallasi Z, Svane IM, Swanton C, Quezada SA, Jakobsen SN, Eklund AC, Hadrup SR . Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. Nat Biotechnol, 2016,34(10):1037-1045.

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

基于迁移学习的MHC-I型抗原表位呈递预测

MHC-I epitope presentation prediction based on transfer learning

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 39

相关文章 4

编辑推荐

Metrics

[1]	秦丽丽, 李毅坚, 梁兆端, 陈蕾, 李文慧, 陈超, 黄亚灵, 张乐, 刘松明, 邱思, 葛玉萍, 彭文婷, 林欣欣, 张秀清, 董旋, 李波. 基于体细胞突变数据库筛选免疫原性结直肠癌高频新抗原的方法[J]. 遗传, 2020, 42(6): 599-612.
[2]	张强, 顾明亮. 单细胞测序技术及其在乳腺癌研究中的应用[J]. 遗传, 2020, 42(3): 250-268.
[3]	卢涣滋,王迪侃,王智. HPV阳性口咽癌患者预后与T细胞浸润和新抗原负荷相关性分析[J]. 遗传, 2019, 41(8): 725-735.
[4]	许崇凤,段子渊. 中华民族永生细胞库在生命科学研究中的支撑作用[J]. 遗传, 2017, 39(1): 75-86.